Xeris Biopharma Holdings (XERS) Non-Current Debt (2023 - 2026)

Xeris Biopharma Holdings has reported Non-Current Debt for 4 years, with the latest figure at $221.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 1.57% year-over-year to $221.2 million; the trailing twelve-month figure through Mar 2026 stood at $221.2 million (up 1.57% YoY), and the FY2025 full-year result was $220.3 million, up 1.53% from the prior year.
• Non-Current Debt for Q1 2026 stood at $221.2 million, roughly flat from $220.3 million in the prior quarter.
• The five-year high for Non-Current Debt was $221.2 million in Q1 2026, with the low at $190.9 million in Q4 2023.
• Historically, Non-Current Debt has averaged $215.1 million across 4 years, with a median of $218.6 million in 2025.
• Annual changes were most pronounced in 2024 — Non-Current Debt climbed 13.66% — and 2025, when it advanced 1.53%.
• Xeris Biopharma Holdings' Non-Current Debt stood at $190.9 million in 2023, then increased by 13.66% to $217.0 million in 2024, then rose by 1.53% to $220.3 million in 2025, then advanced by 0.4% to $221.2 million in 2026.
• The last three Non-Current Debt figures came in at $221.2 million (Q1 2026), $220.3 million (Q4 2025), and $219.5 million (Q3 2025), per Business Quant data.